CytomX TherapeuticsCTMX
CTMX
0
Funds holding %
of 7,390 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
620% more call options, than puts
Call options by funds: $36K | Put options by funds: $5K
20% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 10
14% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 21
1% more funds holding
Funds holding: 69 [Q3] → 70 (+1) [Q4]
5.84% less ownership
Funds ownership: 65.53% [Q3] → 59.69% (-5.84%) [Q4]
20% less capital invested
Capital invested by funds: $60.4M [Q3] → $48.1M (-$12.3M) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for CTMX.
Financial journalist opinion
Based on 7 articles about CTMX published over the past 30 days
Positive
Zacks Investment Research
1 week ago
CytomX Therapeutics (CTMX) Upgraded to Strong Buy: Here's What You Should Know
CytomX Therapeutics (CTMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Positive
Zacks Investment Research
2 weeks ago
CytomX Therapeutics (CTMX) Tops Q4 Earnings and Revenue Estimates
CytomX Therapeutics (CTMX) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of a loss of $0.20 per share. This compares to earnings of $0.01 per share a year ago.

Neutral
Seeking Alpha
2 weeks ago
CytomX Therapeutics, Inc. (CTMX) Q4 2024 Earnings Call Transcript
CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q4 2024 Results Conference Call March 6, 2025 5:00 PM ET Company Participants Chris Ogden - CFO Sean McCarthy - Chairman and CEO Conference Call Participants Roger Song - Jefferies Joe Catanzaro - Piper Sandler Anupam Rama - JPMorgan Peter Lawson - Barclays Operator Good afternoon, everyone. Thank you for standing by.

Neutral
GlobeNewsWire
2 weeks ago
CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update
- Continued progress with lead program, CX-2051 (EpCAM PROBODY® Topo-1 ADC), in Phase 1a study in advanced colorectal cancer with initial Phase 1a clinical data to be presented in 1H 2025 -

Neutral
GlobeNewsWire
2 weeks ago
CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12, 2025, at 3:00 p.m. ET.

Positive
Zacks Investment Research
2 weeks ago
CytomX Gears Up to Report Q4 Earnings: What Should Investors Expect?
On CTMX's fourth-quarter 2024 earnings call, investors can expect updates regarding the developmental programs for its clinical-stage candidates.

Neutral
GlobeNewsWire
3 weeks ago
CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report full year 2024 financial results on Thursday, March 6, 2025, after the close of U.S. markets.

Positive
Zacks Investment Research
2 months ago
All You Need to Know About CytomX Therapeutics (CTMX) Rating Upgrade to Strong Buy
CytomX Therapeutics (CTMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Neutral
GlobeNewsWire
2 months ago
CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update
- Encouraging progress supports near-term focus on lead wholly-owned program, CX-2051 (EpCAM PROBODY® ADC). Initial Phase 1a clinical data in advanced metastatic colorectal cancer (CRC) are anticipated in the first half of 2025 -

Positive
Zacks Investment Research
3 months ago
CytomX Therapeutics (CTMX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
CytomX Therapeutics (CTMX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Charts implemented using Lightweight Charts™